10x Genomics is trading 4.1% lower at $77.35 on October 12, 2026; no confirmed company-specific catalyst has been identified. - Recent coverage has discussed the Fred Hutch research collaboration and analyst price-target changes, but does not link either to the decline. - The broader market is nearly flat, and available biotech-sector coverage does not show a same-direction decline explaining the move. - Recent positive company news does not account for today’s drop; the cause remains unclear.